Table 4.
Geometric means and 95 % confidence intervals of IGFBP-3 (ng/mL) concentrations by quintiles of sex steroid hormones of the U.S. male population of 20 years or older, NHANES III 1988–1991
| Sex steroid hormones | Model 1†
|
Model 2†
|
Model 3§
|
|||
|---|---|---|---|---|---|---|
| Mean | 95 % CI | Mean | 95 % CI | Mean | 95 % CI | |
| Total testosterone (ng/mL) | ||||||
| ≤3.67 | 4,477 | 4,331–4,627 | 4,493 | 4,348–4,642 | 4,313 | 4,162–4,470 |
| 3.68–4.64 | 4,303 | 4,118–4,496 | 4,316 | 4,110–4,531 | 4,184 | 3,968–4,411 |
| 4.65–5.62 | 4,471 | 4,244–4,710 | 4,476 | 4,264–4,700 | 4,444 | 4,238–4,660 |
| 5.62–6.91 | 4,293 | 4,143–4,448 | 4,272 | 4,133–4,416 | 4,341 | 4,200–4,487 |
| >6.91 | 4,222 | 4,032–4,422 | 4,215 | 4,077–4,357 | 4,428 | 4,309–4,551 |
| Slope, P-trend* | −0.01 | 0.06 | −0.01 | 0.01 | 0.01 | 0.23 |
| Free testosterone (ng/mL) | ||||||
| ≤0.069 | 4,318 | 4,099–4,549 | 4,329 | 4,134–4,534 | 4,234 | 4,032–4,447 |
| 0.070–0.092 | 4,347 | 4,128–4,577 | 4,345 | 4,091–4,613 | 4,290 | 4,026–4,571 |
| 0.093–0.113 | 4,390 | 4,207–4,581 | 4,401 | 4,226–4,585 | 4,375 | 4,204–4,554 |
| 0.113–0.14 | 4,414 | 4,224–4,612 | 4,405 | 4,222–4,595 | 4,421 | 4,247–4,601 |
| >0.14 | 4,258 | 4,036–4,492 | 4,253 | 4,054–4,462 | 4,359 | 4,156–4,572 |
| Slope, P-trend* | −0.003 | 0.71 | −0.003 | 0.65 | 0.01 | 0.36 |
| Total estradiol (pg/mL) | ||||||
| ≤28.56 | 4,588 | 4,449–4,732 | 4,593 | 4,445–4,745 | 4,574 | 4,392–4,765 |
| 28.57–33.29 | 4,359 | 4,160–4,567 | 4,371 | 4,173–4,578 | 4,356 | 4,134–4,591 |
| 33.30–38.66 | 4,311 | 4,141–4,487 | 4,308 | 4,151–4,471 | 4,310 | 4,152–4,474 |
| 38.67–46.2 | 4,381 | 4,159–4,615 | 4,370 | 4,162–4,588 | 4,388 | 4,168–4,619 |
| >46.2 | 4,121 | 3,936–4,316 | 4,120 | 3,950–4,297 | 4,130 | 3,950–4,320 |
| Slope, P-trend* | −0.02 | 0.01 | −0.02 | 0.01 | −0.02 | 0.05** |
| Free estradiol (pg/mL) | ||||||
| ≤0.70 | 4,415 | 4,265–4,751 | 4,426 | 4,273–4,586 | 4,423 | 4,239–4,615 |
| 0.71–0.85 | 4,448 | 4,301–4,600 | 4,457 | 4,320–4,597 | 4,455 | 4,308–4,607 |
| 0.86–1.0 | 4,346 | 4,161–4,539 | 4,335 | 4,138–4,542 | 4,334 | 4,139–4,538 |
| 1.1–1.20 | 4,313 | 4,152–4,481 | 4,317 | 4,181–4,459 | 4,319 | 4,186–4,456 |
| >1.20 | 4,225 | 4,013–4,448 | 4,213 | 4,014–4,422 | 4,217 | 3,998–4,449 |
| Slope, P-trend* | −0.01 | 0.11 | −0.01 | 0.08 | −0.01 | 0.17 |
| SHBG (nmol/L) | ||||||
| ≤24.0 | 4,500 | 4,326–4,681 | 4,501 | 4,343–4,665 | 4,501 | 4,316–4,694 |
| 24.1–31.62 | 4,481 | 4,292–4,679 | 4,483 | 4,296–4,678 | 4,472 | 4,279–4,675 |
| 31.63–40.52 | 4,202 | 4,040–4,369 | 4,201 | 4,053–4,353 | 4,195 | 4,051–4,344 |
| 40.53–53.50 | 4,335 | 4,191–4,484 | 4,347 | 4,208–4,490 | 4,353 | 4,203–4,508 |
| >53.50 | 4,174 | 3,965–4,395 | 4,157 | 3,957–4,367 | 4,171 | 3,963–4,391 |
| Slope, P-trend* | −0.02 | 0.01 | −0.02 | 0.005 | −0.02 | 0.02** |
| Androstanediol glucuronide (ng/mL) | ||||||
| ≤6.72 | 4,310 | 4,123–4,504 | 4,333 | 4,143–4,532 | Not applicable | |
| 6.73–9.68 | 4,279 | 4,098–4,469 | 4,281 | 4,107–4,462 | ||
| 9.69–12.77 | 4,332 | 4,176–4,494 | 4,332 | 4,173–4,497 | ||
| 12.78–17.82 | 4,476 | 4,313–4,644 | 4,466 | 4,297–4,642 | ||
| >17.82 | 4,321 | 4,155–4,494 | 4,313 | 4,161–4,470 | ||
| Slope, P-trend* | 0.005 | 0.35 | 0.003 | 0.4 | ||
SHBG sex hormone-binding globulin
From a linear regression model of sex steroid hormones on IGFBP-3 adjusted for age and race/ethnicity
Same as model 1 plus adjustment for body mass index, waist circumference, diabetes, cigarette smoking, alcohol consumption, and physical activity
Same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted, and free testosterone and free estradiol mutually adjusted
Change in IGFBP-3 concentration in ng/mL per one quintile change in sex steroid hormone concentration
The −0.02 slope for total estradiol and SHBG was based on the logarithmic distribution of IGFBP-3 and corresponded to a 82 ng/mL decrease in IGFBP-3 per quintile change of estradiol and 74 ng/mL decrease in IGFBP-3 per quintile change of SHBG in the natural scale